SUPPLEMENTARY APPENDIX

Human leukocyte antigen class II expression is a good prognostic factor in adult T-cell leukemia/lymphoma

Mai Takeuchi,[1] Hiroaki Miyoshi,[1] Naoko Asano,[2] Noriaki Yoshida,[1,3] Kyohei Yamada,[1] Eriko Yanagida,[1] Mayuko Moritsubo,[1] Michiko Nakata,[1] Takeshi Umeno,[1] Takaharu Suzuki,[1] Satoru Komaki,[1] Hiroko Muta,[1] Takuya Furuta,[1] Masao Seto[1] and Koichi Ohshima[1]

[1]Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka; [2]Department of Molecular Diagnostics, Nagano Prefectural Shinshu Medical Center, Suzaka, Nagano and [3]Department of Clinical Studies, Radiation Effects Research Foundation, Hiroshima, Japan

 doi:10.3324/haematol.2018.205567

Received: August 28, 2018.

Accepted: January 9, 2019.

Pre-published: January 10, 2019.

Correspondence: *KOICHI OHSHIMA* - ohshima_kouichi@med.kurume-u.ac.jp



Supplemental figure 1. Expression patterns of PD-L1 and PD-1.
A) Programmed death ligand 1 (PD-L1) expression on microenvironmental stromal cells (miPD-L1). miPD-L1s have irregular shaped cytoplasm with round small nuclei without atypia. B) PD-L1 expression on neoplastic cells (nPD-L1). PD-L1-positive tumor cells have large atypical nuclei with well-circumscribed cytoplasm. C) Programmed cell death 1 (PD-1) expression on tumor infiltrating lymphocytes (TILs). PD-1 positive TILs are small and scatter among tumor cells. D) PD-1 expression on tumor cells. PD-1 expressing tumor cells are large and have atypical nuclei.



Supplemental figure 2. Association of HLA class II, PD-L1, and PD-1 expression.
Heatmap comparing the expression patterns of human leukocyte antigen (HLA) class II, programmed death ligand 1 (PD-L1), and programmed cell death 1 (PD-1). White, negative or PD-1$^+$ tumor-infiltrating lymphocytes (TILs) < 10 per high power field (/hpf); gray, positive or PD-1$^+$ TILs ≥10/hpf.

Supplemental Table 1. Chemotherapy regimens.

Regimen	HLA class II^{+} (n=44)	%	HLA class II^{-} (n=88)	%	p
VCAP-AMP-VECP	14	31.8	24	27.2	0.5884
CHOP	7	15.9	25	28.4	0.1050
COP	4	9.1	11	12.5	0.5541
EPOCH	4	9.1	6	6.8	0.6462
VEPA	3	6.8	4	4.6	0.5898
Others	4	9.1	9	10.2	0.8354
No chemotherapy	8	18.2	9	10.2	0.2083

HLA, human leukocyte antigen; VCAP-AMP-VECP, vincristine, cyclophosphamide, doxorubicin, prednisone–doxorubicin, ranimustine, prednisone–vindesine, etoposide, carboplatin and prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; COP, cyclophosphamide, doxorubicin, prednisone; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; VEPA, vinblastine, etoposide, prednisone, doxorubicin; p, p-value.